Hoagland B et al. Journal of the International AIDS Society 2017, 20:21472 http://www.jiasociety.org/index.php/jias/article/view/21472 | http://dx.doi.org/10.7448/IAS.20.1.21472
Research article
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project Brenda Hoagland1, Ronaldo I. Moreira1, Raquel B. De Boni1 Esper G. Kallas2, José Valdez Madruga3, Ricardo Vasconcelos2, Silvia Goulart3, Thiago S. Torres1, Luana M. S. Marins1, Peter L. Anderson4, Paula M Luz1 Iuri da Costa Leite1, Albert Y. Liu5, Valdilea G. Veloso*1 and Beatriz Grinsztejn *1§ for the PrEP Brasil Study Team § Corresponding author: Beatriz Grinsztejn, INI/FIOCRUZ, Avenida Brasil 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil. Tel: 55-21-3865-9128. [email protected] *Contributed equally as last authors Clinical Trial Number 01989611
Abstract Introduction: The efficacy of pre-exposure prophylaxis (PrEP) in preventing sexual acquisition of human immunodeficiency virus (HIV) is well established. Little is known about the feasibility of PrEP implementation in middle-income settings with concentrated epidemics among men who have sex with men (MSM) and transgender women (TGW). Methods: PrEP Brasil is a prospective, multicentre, open-label demonstration project assessing PrEP delivery in the context of the Brazilian Public Health System. HIV-uninfected MSM and TGW in 3 referral centres in Rio de Janeiro and São Paulo were evaluated for eligibility and offered 48 weeks of daily emtricitabine/tenofovir for PrEP. Concentrations of tenofovir diphosphate in dried blood spot samples (DBS) at week 4 after enrolment (early adherence) were measured. Predictors of drug levels were assessed using ordinal logistic regression models considering the DBS drug level as a 3 level variable (
Research article
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project Brenda Hoagland1, Ronaldo I. Moreira1, Raquel B. De Boni1 Esper G. Kallas2, José Valdez Madruga3, Ricardo Vasconcelos2, Silvia Goulart3, Thiago S. Torres1, Luana M. S. Marins1, Peter L. Anderson4, Paula M Luz1 Iuri da Costa Leite1, Albert Y. Liu5, Valdilea G. Veloso*1 and Beatriz Grinsztejn *1§ for the PrEP Brasil Study Team § Corresponding author: Beatriz Grinsztejn, INI/FIOCRUZ, Avenida Brasil 4365, Manguinhos, Rio de Janeiro 21040-360, Brazil. Tel: 55-21-3865-9128. [email protected] *Contributed equally as last authors Clinical Trial Number 01989611
Abstract Introduction: The efficacy of pre-exposure prophylaxis (PrEP) in preventing sexual acquisition of human immunodeficiency virus (HIV) is well established. Little is known about the feasibility of PrEP implementation in middle-income settings with concentrated epidemics among men who have sex with men (MSM) and transgender women (TGW). Methods: PrEP Brasil is a prospective, multicentre, open-label demonstration project assessing PrEP delivery in the context of the Brazilian Public Health System. HIV-uninfected MSM and TGW in 3 referral centres in Rio de Janeiro and São Paulo were evaluated for eligibility and offered 48 weeks of daily emtricitabine/tenofovir for PrEP. Concentrations of tenofovir diphosphate in dried blood spot samples (DBS) at week 4 after enrolment (early adherence) were measured. Predictors of drug levels were assessed using ordinal logistic regression models considering the DBS drug level as a 3 level variable (
